Atea Pharmaceuticals (AVIR) Accumulated Expenses (2019 - 2026)

Atea Pharmaceuticals' Accumulated Expenses history runs 8 years deep, the most recent figure standing at $2.3 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses fell 20.15% year-over-year to $2.3 million in Q1 2026; TTM through Mar 2026 was $2.3 million, a 20.15% decrease from a year earlier, with the FY2025 full-year figure at $6.4 million, up 9.04% from the prior year.
• Accumulated Expenses slipped to $2.3 million in Q1 2026 per AVIR's latest filing, from $6.4 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $20.4 million in Q2 2024 and bottomed at $1.9 million in Q1 2022.
• The 5-year median for Accumulated Expenses is $10.9 million (2023), against an average of $10.7 million.
• Across the five-year window, Accumulated Expenses slumped 91.53% in 2022 and surged 471.11% in 2023, its largest moves.
• Year by year, Accumulated Expenses stood at $15.2 million in 2022, then sank by 62.54% to $5.7 million in 2023, then grew by 3.65% to $5.9 million in 2024, then advanced by 9.04% to $6.4 million in 2025, then slumped by 64.68% to $2.3 million in 2026.
• Per Business Quant, the three latest AVIR Accumulated Expenses figures stand at $2.3 million (Q1 2026), $6.4 million (Q4 2025), and $15.8 million (Q3 2025).